Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under a new subscription right plan.
Related Questions
How will the proceeds from the rights issue be allocated—e.g., R&D, pipeline expansion, or debt repayment?
What is the expected price adjustment for the stock once the subscription rights are exercised?
How will the issuance of 1,800,000 subscription rights affect GLPG's diluted earnings per share?
What is the timeline for subscription, allocation, and potential impact on liquidity and volatility?
Could the rights issue trigger any anti-dilution clauses or trigger convertible securities for existing shareholders?
How does the size of this rights issue compare to Galapagos' previous capital raises and to peers in the biotech sector?
What is the market's perception of the capital raise—are investors viewing it as a growth catalyst or a sign of cash needs?
What is the potential impact on the company's credit rating and future financing costs?
Will the new subscription right plan lead to a secondary offering or increase in free float?
What regulatory approvals or shareholder votes are required for the plan to be executed?